Drug intelligence / Profile preview

A33Ab-US-Exo + doxorubicin

Development stage: Preclinical
Modality: Small Molecules, Antibody-Based Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

A33Ab-US-Exo + doxorubicin is a **combination drug** consisting of exosomes derived from A33-positive colon cancer cells, coated with A33 antibody-functionalized superparamagnetic iron oxide nanoparticles (A33Ab-US-Exo), and loaded with the chemotherapy agent **doxorubicin**[1]. The A33 antibody targets the A33 antigen, highly expressed in certain colon cancer cells, and the exosome-based delivery system provides tumor-specific targeting and increased uptake of doxorubicin in these cells. This combination results in antiproliferative effects, tumor growth inhibition, and increased survival in mouse models of colon cancer, while reducing cardiotoxicity compared to free doxorubicin. The mechanism of action integrates exosome-based targeted delivery with the DNA-intercalating, topoisomerase II inhibiting activity of doxorubicin. This delivery system represents a novel approach to targeted chemotherapy for A33-positive malignancies[1].

Other names: A33Ab-US-Exo/Dox

Targets

GPA33 (Glycoprotein A33)TOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on A33Ab-US-Exo + doxorubicin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A33Ab-US-Exo + doxorubicin.

Explore the full profile